-
Basel, April 5, 2022 — Novartis today announced new long-term data from the Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension that demonstrated long-term efficacy and safety of Kesimpta® (ofatumumab), with continued reduced risk of disability worsening, for people living with relapsing multiple sclerosis following up to four…NeuroscienceNeurodegenerative Disease
-
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing regimen for Gilenya. In August 2020, the U.S. Federal District Court for the District of Delaware issued a favorable decision in the Gilenya patent…NeuroscienceNeurodegenerative Disease
-
Basel, March 2, 2022 — Today, Novartis announced that new data from the ALITHIOS open-label extension study was published in the peer-reviewed Multiple Sclerosis Journal. The data showed that with up to 3.5 years of treatment with Kesimpta® (ofatumumab), no incidences of opportunistic infections were reported, and observed COVID-19 infections…NeuroscienceMusculoskeletal Diseases
-
Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.Scientific ResearchNeuroscienceNeurodegenerative Disease
-
Basel, March 18, 2022 — Novartis today announced that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab). This data was compiled from the ongoing, open-label, long-term extension phase 3b ALITHIOS study and from…NeuroscienceNeurodegenerative Disease
-
The digital press release with multimedia content can be accessed here:Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
Basel, February 16, 2021 — Novartis announced today new multicenter survey results showing that people living with multiple sclerosis (MS) and nurses prefer the Sensoready® autoinjector pen for self-administration of Kesimpta® (ofatumumab) over other autoinjectors used for other disease-modifying therapies in MS1. These data, which will be…NeuroscienceInnovation
-
Basel, February 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in…Reimagine MedicineNeuroscienceMedical InnovationsLiving With Disease
-
The digital press release with multimedia content can be accessed here:Neuroscience
-
Basel, October 14, 2021 — Today, Novartis announced data demonstrating the safety of Kesimpta® (ofatumumab) over extended exposure (~3.5 years) in patients with relapsing forms of multiple sclerosis (RMS).1 These data—presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place…NeuroscienceNeurodegenerative Disease
-
Basel, June 22, 2021 — Today, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab) over 3.5 years. The ongoing open label extension of the ALITHIOS study includes 1,703 people living with MS taking Kesimpta for up to 5 years. At the time…NeuroscienceInnovation
-
Basel, October 7, 2021 — Novartis announced today it will present 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place digitally on October 13-15, 2021. The data being presented spans a comprehensive MS portfolio, emphasizing the company’s commitment to…NeuroscienceClinical Trials
Pagination
- 1
- 2
- 3
- 4
- › Next page